Angiotensin receptor blockade and stereotactic body radiation therapy for early stage lung cancer ARB & SBRT for early stage lung cancer

References

• Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJM, McRae SE, Widder J, Feng L, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–637. doi:10.1016/S1470-2045(15)70168-3.
   PubMed Web of Science ®Google Scholar
• Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, Straube WL, Nedzi LA, McGarry RC, Robinson CG, et al. Stereotactic body radiation therapy for operable early-stage lung cancer findings from the NRG oncology RTOG 0618 trial. JAMA Oncol. 2018;4(9):1263–1266. doi:10.1001/jamaoncol.2018.1251.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Shibamoto Y, Hashizume C, Kondo T, Iwata H, Tomita N, Ogino H. Repeat stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell lung cancer and lung metastasis after first SBRT. Radiat Oncol. 2018;13(1):1–7. doi:10.1186/s13014-018-1080-4.
   PubMedGoogle Scholar
• Al X, Zink AN, Holm AA, Billington CJ, Kotz CM. S. et. 乳鼠心肌提取 HHS public access. Physiol Behav. 2017;176:139–148. doi:10.1016/j.physbeh.2017.03.040.
   PubMedGoogle Scholar
• Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147(5):992–1009. doi:10.1016/j.cell.2011.11.016.
   PubMed Web of Science ®Google Scholar
• Kirshner J, Jobling MF, Pajares MJ, Ravani SA, Glick AB, Lavin MJ, Koslov S, Shiloh Y, Barcellos-Hoff MH. Inhibition of transforming growth factor-β1 signaling attenuates ataxia telangiectasia mutated activity in response to genotoxic stress. Cancer Res. 2006;66(22):10861–10869. doi:10.1158/0008-5472.CAN-06-2565.
   PubMed Web of Science ®Google Scholar
• Jakowlew SB. Transforming growth factor-β in cancer and metastasis. Cancer Metastasis Rev. 2006;25(3):435–457. doi:10.1007/s10555-006-9006-2.
   PubMed Web of Science ®Google Scholar
• Miyazono K, Katsuno Y, Koinuma D, Ehata S, Morikawa M. Intracellular and extracellular TGF-β signaling in cancer: some recent topics. Front Med. 2018;12(4):387–411. doi:10.1007/s11684-018-0646-8.
   PubMed Web of Science ®Google Scholar
• Bouquet F, Pal A, Pilones KA, Demaria S, Hann B, Akhurst RJ, Babb JS, Lonning SM, DeWyngaert JK, Formenti SC, et al. TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res. 2011;17(21):6754–6765. doi:10.1158/1078-0432.CCR-11-0544.
   PubMed Web of Science ®Google Scholar
• Gunderson AJ, Yamazaki T, McCarty K, Fox N, Phillips M, Alice A, Blair T, Whiteford M, O’Brien D, Ahmad R, et al. TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking. Nat Commun. 2020;11(1):1–13. doi:10.1038/s41467-020-15404-8.
   PubMed Web of Science ®Google Scholar
• Du S, Bouquet S, Lo C-H, Pellicciotta I, Bolourchi S, Parry R, Barcellos-Hoff MH. Attenuation of the DNA damage response by transforming growth factor-beta inhibitors enhances radiation sensitivity of non - Small-cell lung cancer cells in vitro and in vivo. Int J Radiat Oncol Biol Phys. 2015;91(1):91–99. doi:10.1016/j.ijrobp.2014.09.026.
   PubMed Web of Science ®Google Scholar
• Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JL, Palena C, Schlom J. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances. J Immunother Cancer. 2020;8(1):1–10. doi:10.1136/jitc-2019-000433.
   Web of Science ®Google Scholar
• Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394(10211):1816–1826. doi:10.1016/S0140-6736(19)32317-7.
   PubMed Web of Science ®Google Scholar
• Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-β 1. Am J Physiol - Ren Physiol. 2004;286(2):1–2. doi:10.1152/ajprenal.00139.2003.
   Web of Science ®Google Scholar
• Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009;135(10):1429–1435. doi:10.1007/s00432-009-0587-3.
   PubMed Web of Science ®Google Scholar
• Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(7):1020–1027. doi:10.1001/jamaoncol.2019.0892.
   PubMed Web of Science ®Google Scholar
• Vujaskovic Z, Marks LB, Anscher MS. The physical parameters and molecular events associated with radiation induced lung toxicity. Semin Radiat Oncol. 2000;10(4):296–307. doi:10.1053/srao.2000.9424.
   PubMed Web of Science ®Google Scholar
• Yuan X, Liao Z, Liu Z, Wang L-E, Tucker SL, Mao L, Wang XS, Martel M, Komaki R, Cox JD, et al. Single nucleotide polymorphism at rs1982073:T869C of the TGF β 1 gene is associated with the risk of radiation pneumonitis in patients with non–small-cell lung cancer Treated with definitive radiotherapy. J Clin Oncol. 2009;27(20):3370–3378. doi:10.1200/JCO.2008.20.6763.
   PubMed Web of Science ®Google Scholar
• Gasparini A, Hojjat Salmasian JW. Comorbidity. (2020).
   Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Atkins KM, Rawal B, Chaunzwa TL, Lamba N, Bitterman DS, Williams CL, Kozono DE, Baldini EH, Chen AB, Nguyen PL, et al. Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer. J Am Coll Cardiol. 2019;73(23):2976–2987. doi:10.1016/j.jacc.2019.03.500.
   PubMed Web of Science ®Google Scholar
• Fillon M. Lung cancer radiation may increase the risk of major adverse cardiac events. CA Cancer J Clin. 2019;69(6):435–437. doi:10.3322/caac.21581.
   PubMed Web of Science ®Google Scholar
• Atkins KM, Chaunzwa TL, Lamba N, Bitterman DS, Rawal B, Bredfeldt J, Williams CL, Kozono DE, Baldini EH, Nohria A, et al. Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non–small cell lung cancer. JAMA Oncol. 2020;7(2):206–19.
   Web of Science ®Google Scholar
• Ehanire T, Ren L, Bond J, Medina M, Li G, Bashirov L, Chen L, Kokosis G, Ibrahim M, Selim A, et al. Angiotensin II stimulates canonical TGF-β signaling pathway through angiotensin type 1 receptor to induce granulation tissue contraction. J Mol Med. 2015;93(3):289–302. doi:10.1007/s00109-014-1211-9.
   PubMed Web of Science ®Google Scholar
• Frank GD, Saito S, Motley ED, Sasaki T, Ohba M, Kuroki T, Inagami T, Eguchi S. Requirement of Ca2+ and PKCδ for Janus Kinase 2 activation by angiotensin II: involvement of PYK2. Mol Endocrinol. 2002;16(2):367–377. doi:10.1210/mend.16.2.0768.
   PubMedGoogle Scholar
• Fukuda N, Hu W-Y, Kubo A, Kishioka H, Satoh C, Soma M, Izumi Y, Kanmatsuse K. Angiotensin II upregulates transforming growth factor-β type I receptor on rat vascular smooth muscle cells. Am J Hypertens. 2000;13(2):191–198. doi:10.1016/S0895-7061(99)00152-1.
   PubMed Web of Science ®Google Scholar
• Matavelli, H. M. S LC. AT2 receptor activities and pathophysiological implications. Cardiovasc Pharmacol. 2015;176(148)226–32.
   Google Scholar
• Kawabata A, Baoum A, Ohta N, Jacquez S, Seo G-M, Berkland C, Tamura M. Intratracheal administration of a nanoparticle-based therapy with the angiotensin II type 2 receptor gene attenuates lung cancer growth. Cancer Res. 2012;72(8):2057–2067. doi:10.1158/0008-5472.CAN-11-3634.
   PubMed Web of Science ®Google Scholar